Quick Information
- Category:
- Healthcare
- Pricing:
- Contact Sales
- Platforms:
- Web, Cloud
- Free Plan:
- No
- Last Verified:
- October 2026
What Is Insilico Medicine?
Insilico Medicine is an AI drug discovery company built around its generative AI platform, Pharma.AI. Its lead candidate, rentosertib (also known as ISM001-055), is an inhibitor of TNIK developed with the platform for idiopathic pulmonary fibrosis (IPF). In a placebo-controlled Phase 2a trial of 71 participants in China, rentosertib was well tolerated and showed dose-dependent improvements in forced vital capacity after 12 weeks. The results were published in Nature Medicine. Planned next steps include a kidney fibrosis trial and an inhaled version for IPF. A Phase 2b or Phase 3 start was not confirmed in the sources.
The company also became a public name. Insilico listed on the Hong Kong Stock Exchange in late December 2025 under 03696.HK, raising about HKD 2.28 billion (roughly US$290 million) in a debut described as the first AI-driven biotech listed under Chapter 8.05. The retail tranche was oversubscribed 1,427 times, and cornerstone investors included Eli Lilly, Tencent and Temasek. It was Insilico's fourth attempt to list. Its prospectus reported $85.8 million in 2024 revenue and a $17.4 million net loss. As with any drug developer, a promising early trial does not guarantee approval, and no AI-designed drug has yet reached the market.
Insilico suits pharma partners, investors and researchers following AI-designed medicines. Compare Recursion, Isomorphic Labs and Schrödinger. Browse the Healthcare tools directory for more.
What Can You Use Insilico Medicine For?
Target discovery
Generative AI identifies drug targets.
Molecule design
Designs candidate compounds.
Pipeline development
Advances AI-designed drugs through trials.
Insilico Medicine Features
- Pharma.AI — Generative AI platform for drug discovery.
- Rentosertib (ISM001-055) — TNIK inhibitor with Phase 2a data in IPF.
- Public listing — Listed in Hong Kong as 03696.HK.
- Pharma investors — Eli Lilly was among cornerstone investors.
Who Is Insilico Medicine For?
- Pharma and biotech partners — Access AI-designed candidates and platform.
- Investors and researchers — Follow a leading AI drug developer.
Insilico Medicine Pros & Limitations
What We Like
- Clinical-stage proof point with published Phase 2a data
- Public company with disclosed financials
- Backed by major cornerstone investors
Limitations
- Lead drug has not progressed beyond Phase 2a in the sources found
- Drug development carries high failure risk
- Platform pricing is not public
Insilico Medicine Pricing
| Plan | Price | Main Features |
|---|---|---|
| Partnerships and licensing | Custom | Pharma.AI platform access, collaborations and drug candidates |
Pricing was last verified October 2026. Check the official website for the latest pricing.
AI Listing Jungle Ranking
- Global Rank:
- #1708
- Overall Score:
- 0.0/100
- Monthly Users:
- –
- Rank Change:
- ▼ 374
This ranking reflects AI Listing Jungle's own independent scoring methodology and is not an endorsement by Insilico Medicine or its company. How Our Rankings Work
Frequently Asked Questions
What is rentosertib?
Insilico's TNIK inhibitor for idiopathic pulmonary fibrosis, discovered with its Pharma.AI platform.
Is Insilico public?
Yes, it listed on the Hong Kong Stock Exchange in late December 2025 as 03696.HK.
How big was the Phase 2a trial?
71 participants in a placebo-controlled study in China.
How much does it cost?
There is no public price; it works through partnerships.
Our Take
Insilico is one of the clearest tests of whether AI-designed drugs work in humans, and its Phase 2a data is encouraging.
The real verdict comes from later-stage trials.
Insilico Medicine Alternatives
Insilico Medicine Comparisons
Ready to try Insilico Medicine?
Visit the official website to get started.
Visit Official WebsiteAI Listing Jungle is an independent AI tools directory. Product names, logos, and trademarks belong to their respective owners.